vs
Side-by-side financial comparison of Moderna (MRNA) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
Moderna is the larger business by last-quarter revenue ($1.0B vs $766.5M, roughly 1.3× SCANSOURCE, INC.). SCANSOURCE, INC. runs the higher net margin — 2.2% vs -19.7%, a 21.8% gap on every dollar of revenue. On growth, SCANSOURCE, INC. posted the faster year-over-year revenue change (2.5% vs -45.4%). SCANSOURCE, INC. produced more free cash flow last quarter ($28.9M vs $-880.0M). Over the past eight quarters, SCANSOURCE, INC.'s revenue compounded faster (0.9% CAGR vs -45.0%).
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
MRNA vs SCSC — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $766.5M |
| Net Profit | $-200.0M | $16.5M |
| Gross Margin | 79.6% | 13.4% |
| Operating Margin | -25.6% | 2.3% |
| Net Margin | -19.7% | 2.2% |
| Revenue YoY | -45.4% | 2.5% |
| Net Profit YoY | -1638.5% | -3.3% |
| EPS (diluted) | $-0.51 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $766.5M | ||
| Q3 25 | $1.0B | $739.6M | ||
| Q2 25 | — | $812.9M | ||
| Q1 25 | — | $704.8M | ||
| Q4 24 | $966.0M | $747.5M | ||
| Q3 24 | $1.9B | $775.6M | ||
| Q2 24 | — | $746.1M | ||
| Q1 24 | — | $752.6M |
| Q4 25 | — | $16.5M | ||
| Q3 25 | $-200.0M | $19.9M | ||
| Q2 25 | — | $20.1M | ||
| Q1 25 | — | $17.4M | ||
| Q4 24 | $-1.1B | $17.1M | ||
| Q3 24 | $13.0M | $17.0M | ||
| Q2 24 | — | $16.1M | ||
| Q1 24 | — | $12.8M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | 79.6% | 14.5% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | 23.5% | 13.6% | ||
| Q3 24 | 72.4% | 13.1% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 12.6% |
| Q4 25 | — | 2.3% | ||
| Q3 25 | -25.6% | 3.5% | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | -129.0% | 2.5% | ||
| Q3 24 | -3.8% | 2.3% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 2.3% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | -19.7% | 2.7% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | -115.9% | 2.3% | ||
| Q3 24 | 0.7% | 2.2% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | $0.75 | ||
| Q3 25 | $-0.51 | $0.89 | ||
| Q2 25 | — | $0.87 | ||
| Q1 25 | — | $0.74 | ||
| Q4 24 | $-2.91 | $0.70 | ||
| Q3 24 | $0.03 | $0.69 | ||
| Q2 24 | — | $0.66 | ||
| Q1 24 | — | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $83.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.3B | $910.9M |
| Total Assets | $12.1B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $83.5M | ||
| Q3 25 | $1.1B | $124.9M | ||
| Q2 25 | — | $126.2M | ||
| Q1 25 | — | $146.3M | ||
| Q4 24 | $1.9B | $110.5M | ||
| Q3 24 | $1.6B | $145.0M | ||
| Q2 24 | — | $185.5M | ||
| Q1 24 | — | $159.1M |
| Q4 25 | — | $910.9M | ||
| Q3 25 | $9.3B | $914.0M | ||
| Q2 25 | — | $906.4M | ||
| Q1 25 | — | $901.7M | ||
| Q4 24 | $10.9B | $900.7M | ||
| Q3 24 | $11.9B | $920.9M | ||
| Q2 24 | — | $924.3M | ||
| Q1 24 | — | $944.1M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | $12.1B | $1.7B | ||
| Q2 25 | — | $1.8B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | $14.1B | $1.7B | ||
| Q3 24 | $15.8B | $1.8B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-847.0M | $30.8M |
| Free Cash FlowOCF − Capex | $-880.0M | $28.9M |
| FCF MarginFCF / Revenue | -86.6% | 3.8% |
| Capex IntensityCapex / Revenue | 3.2% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $30.8M | ||
| Q3 25 | $-847.0M | $23.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $66.1M | ||
| Q4 24 | $825.0M | $-6.2M | ||
| Q3 24 | $-1.6B | $44.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $160.2M |
| Q4 25 | — | $28.9M | ||
| Q3 25 | $-880.0M | $20.8M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.6M | ||
| Q4 24 | $303.0M | $-8.2M | ||
| Q3 24 | $-1.7B | $42.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $157.7M |
| Q4 25 | — | 3.8% | ||
| Q3 25 | -86.6% | 2.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 9.2% | ||
| Q4 24 | 31.4% | -1.1% | ||
| Q3 24 | -92.2% | 5.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 21.0% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | 3.2% | 0.3% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 54.0% | 0.3% | ||
| Q3 24 | 8.1% | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | -120.46× | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
